Sorafenib in Advanced Hepatocellular Carcinoma
Josep Maria Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip a. Hilgard, Edward John Gane, Jean Frédéric Blanc, André Cosme de Oliveira, Armando Santoro, Jean‐Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F. Greten, Peter R. Galle, Jean François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, Marius Moscovici, D. Voliotis, Jordi Bruix
New England Journal of Medicine · 2008 · 13,250 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P. a., Gane, E. J., Blanc, J. F., Oliveira, A. C. de, Santoro, A., Raoul, J., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Häussinger, D., … Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378–390. https://doi.org/10.1056/nejmoa0708857
In text: (Llovet et al., 2008)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. CONCLUSIONS: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)
Related papers
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer2004
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency2015
- Comprehensive molecular characterization of human colon and rectal cancer2012
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma2020
- Genetic Alterations during Colorectal-Tumor Development1988
Metadata from OpenAlex (CC0). Citations are generated from the published record.